scholarly journals Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods

2019 ◽  
Vol 2019 ◽  
pp. 1-10 ◽  
Author(s):  
Huizi Ouyang ◽  
Jiayuan Shen ◽  
Xuhua Huang ◽  
Wenjuan Ma ◽  
Qi Jia ◽  
...  
Keyword(s):  
Chinese Medicine ◽  
Drug Treatment ◽  
Drug Interactions ◽  
Rat Plasma ◽  
Therapeutic Failure ◽  
Metoprolol Tartrate ◽  
Conventional Drug ◽  
Group A ◽  
Group B ◽  
Opposite Tendency

Naoxintong capsule (NXT), a prescribed Chinese medicine, has been used clinically for more than 20 years and is widely received by patients. We determined five probe drugs, namely, omeprazole (CYP2C19), midazolam (CYP3A4), phenacetin (CYP1A2), tolbutamide (CYP2C9), and dextromethorphan (CYP2D6) to study the potential influences of NXT on the activities of CYP enzymes and assessed the pharmacokinetics effect of NXT on metoprolol tartrate in rat plasma. The study showed that AUC(0–24) and AUC(0–∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL−1 and 292.0 ± 75.1 h·ng·mL−1 in group B; 295.7 ± 62.7 h·ng·mL−1 and 299.5 ± 60.0 h·ng·mL−1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL−1 and 424.9 ± 77.9 h·ng·mL−1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL−1 and 595.3 ± 122.2 h·ng·mL−1 in group A, 760.6 ± 184.9 h·ng·mL−1 and 788.7 ± 211.0 h·ng·mL−1 in group B, and 734.3 ± 118.5 h·ng·mL−1 and 757.2 ± 105.4 h·ng·mL−1 in group C). Moreover, NXT preadministration can enhance the metabolism of metoprolol tartrate and reduce the metabolism of O-demethylmetoprolol. The results indicated that NXT had potential effects in inducing CYP3A4 and inhibiting CYP2D6 in the metabolism of metoprolol tartrate. It suggests that patients who coadministered NXT and metoprolol tartrate should be advised of potential herb-drug interactions (HDIs) to reduce therapeutic failure or accelerated toxicity of conventional drug treatment.

scholarly journals Deqi Sensation in Placebo Acupuncture: A Crossover Study on Chinese Medicine Students

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Zhao-hui Liang ◽  
Chang-cai Xie ◽  
Zi-ping Li ◽  
Xiao-ping Zhu ◽  
Ai-ping Lu ◽  
...  
Keyword(s):  
Chinese Medicine ◽  
Phase I ◽  
Phase Ii ◽  
Clinical Trial Registry ◽  
Placebo Acupuncture ◽  
Real Acupuncture ◽  
Group A ◽  
The Difference ◽  
Two Phases ◽  
Group B

Objective. To evaluate the similarity of deqi sensation of real and noninvasive placebo acupuncture in healthy people with knowledge of Chinese medicine.Methods. In a crossover design, volunteers recruited from Chinese medicine college students were randomized to two groups to receive two phases of intervention with a one-week washout interval. In Group A, the participants were firstly treated by real acupuncture and then by sham needle, and the treatment sequence was reversed in Group B. VAS for pain intensity and deqi sensation was evaluated as outcomes.Results. Sixty-three volunteers were recruited and 60 were included and finished the study. In Group A, VAS was higher in Phase I than in Phase II (P=0.017). Only treatment methods were selected as factor to VAS difference (P=0.046) in ANOVA test. More positive deqi was reported in Group A in Phase I when treated by real acupuncture (P=0.039), but the difference was not significant in Phase II (P=0.301).Conclusion. The noninvasive placebo acupuncture device can effetely simulate the deqi sensation as real acupuncture, but it is less likely to evoke the active effect of deqi in real practice. This trial is registered with Chinese Clinical Trial Registry:ChiCTR-ORC-09000505.

scholarly journals Treatment of knee osteoarthritis with traditional Chinese medicine sloughingClinical efficacy study

2020 ◽  
Vol 8 (2) ◽  
Author(s):  
Liang Wen
Keyword(s):  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Knee Osteoarthritis ◽  
Western Medicine ◽  
Clinical Effect ◽  
Effective Rate ◽  
Control Group ◽  
Observation Group ◽  
Group A ◽  
Group B

Objective: To explore the clinical effect of the treatment of knee osteoarthritis with traditional Chinese medicine.Methods: 152 patients with knee osteoarthritis who were treated in our hospital from July 2018 to April 2020 were divided into two groups. Group A (control group) was treated with conventional western medicine, i.e. celecoxib 200 mg capsule +Glucosamine hydrochloride capsule 0.75g, group B (observation group): the treatment of traditional Chinese medicine sloughing using our experience formula, and further comparative evaluation of the treatment effect of the two groups. Results: the effective rate was 75% in the control group and 92% in the observation group. Conclusion: in the treatment of knee osteoarthritis, traditional Chinese medicine is more effective than western medicine.

scholarly journals Effect and mechanism of YH0618 granule on chemotherapy- induced hair loss in patients with breast cancer: study protocol for a randomized, double-blind, multi-center clinical trial

2019 ◽  
Author(s):  
Jie-shu You ◽  
Li Guo ◽  
Mei Huang ◽  
Xin-lei Shi ◽  
Man-di Lin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Clinical Trial ◽  
Chinese Medicine ◽  
Hair Loss ◽  
Double Blind ◽  
Kidney Deficiency ◽  
Group A ◽  
Group B

Abstract Background: Hair loss is one of the most common side effects of chemotherapy, which can cause persistent negative emotions, further affecting therapeutic effects and reducing the quality of life. However, there is no clinically safe and effective methods to solve the problem at present. Our previous clinical and animal studies showed that a medicinal and edible decoction YH0618 could significantly promote hair growth in cancer patients after chemotherapy, without interfering with the anti-tumor effect of chemotherapy. Besides, the theory of Chinese Medicine believes “Essence of the kidney is reflected on the hair”. Therefore, this study will further explore the efficacy of YH0618 granule on chemotherapy-induced hair loss in patients with breast cancer by a randomized, double-blind, multi-center clinical trial and elucidate the potential mechanism from the aspect of kidney deficiency or renal dysfunction. Methods/Design: Eligible breast cancer patients who will start chemotherapy will be randomly divided into group A (YH0618 granule) and group B (placebo). The chemotherapeutic agents contains Taxanes or/and Anthracyclines, and chemotherapy regimen will last at least 6 cycles with every three weeks a cycle. Subjects assigned to group A will receive YH0618 granules two times a day (6 g each time), 6 days a week, mixing with 300 ml warm water from the first to the fourth chemotherapy cycle. Subjects in group B will receive the placebo granule in the same manner. The primary outcome is the time point of occurrence of hair loss reaching grade II assessed by WHO Toxicity Grading Scale, and objective indexes of hair quality and hair follicle recorded by a hair and scalp detector before the fifth chemotherapy. Secondary outcomes include changes of facial color and thumbnails color, grading of thumbnails ridging, assessment of quality life, fatigue, routine blood test, hepatic and renal function, and some medical indicators which can reflect kidney deficiency in Chinese Medicine. Discussion: This research is of great significance for the treatment of cancer and improving the quality of life of patients. The study may provide the most direct evidence for meeting clinical needs and lay a solid scientific foundation for later product development. Trial registration: The trial was registered on 14 December 2018 at Chinese Clinical Trial Registry: ChiCTR1800020107.

scholarly journals Effect and mechanism of YH0618 granule on chemotherapy- induced hair loss in patients with breast cancer: study protocol for a randomized, double-blind, multi-center clinical trial

2019 ◽  
Author(s):  
Jie-shu You ◽  
Li Guo ◽  
Mei Huang ◽  
Xin-lei Shi ◽  
Man-di Lin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Clinical Trial ◽  
Chinese Medicine ◽  
Hair Loss ◽  
Double Blind ◽  
Kidney Deficiency ◽  
Group A ◽  
Group B

Abstract Background: Hair loss is the one of the most common side effects of chemotherapy, which can cause persistent negative emotions, further affecting therapeutic effects and reducing the quality of life. However, there is no clinically safe and effective methods to solve the problem at present. Our previous clinical and animal studies have shown that YH0618 medicinal and edible decoction could significantly promote hair growth in cancer patients after chemotherapy, and will not interfere with the anti-tumor effect of chemotherapy. Besides, the theory of Chinese Medicine believe “Essence of the kidney is reflected on the hair”. Therefore, this study will further explore the efficacy of YH0618 granule on chemotherapy-induced hair loss in patients with breast cancer by a randomized, double-blind, multi-center clinical trial and elucidate the potential mechanism from the aspect of kidney deficiency or renal dysfunction. Methods/Design: Eligible breast cancer patients who will start chemotherapy will be randomly divided into group A (YH0618 granule) and group B (placebo). The chemotherapeutic agents contains Taxanes or/and Anthracyclines, and chemotherapy regimen will last at least 6 cycles with every three weeks a cycle. Subjects assigned to group A will receive YH0618 granules two times a day (6 g each time), 6 days a week, mixing with 200 ml warm water from the first to the fourth chemotherapy cycle. Subjects in group B will receive the placebo granule in the same manner. The primary outcome end point is successful hair preservation assessed using WHO Toxicity Grading Scale (grade ≤II), and objective indexes of hair loss levels, hair density and quality recorded by a hair and scalp detector before the fifth chemotherapy. Secondary outcomes include assessment of quality life, routine blood test, hepatic and renal function, and some medical indicators which can reflect kidney deficiency in Chinese Medicine. Discussion: This research is of great significance for the treatment of cancer and improving the quality of life of patients. The study may provide the most direct evidence for meeting clinical needs and lay a solid scientific foundation for later product development. Trial Registration: The trial was registered on 14 December 2018 at Chinese Clinical Trial Registry: ChiCTR1800020107. Keywords: Medicinal and edible compound prescription, YH0618 granule, chemotherapy-induced hair loss, Taxanes, Anthracyclines, Kidney deficiency and renal dysfunction, Quality of life.

scholarly journals Comparative Plasma Exposure and Lung Distribution of Two Human Use Commercial Azithromycin Formulations Assessed in Murine Model: A Preclinical Study

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Virginia Rivulgo ◽  
Mónica Sparo ◽  
Mónica Ceci ◽  
Elida Fumuso ◽  
Alejandra Confalonieri ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Lung Tissue ◽  
Murine Model ◽  
Tissue Concentration ◽  
Preclinical Study ◽  
Therapeutic Failure ◽  
Pharmacokinetic Analysis ◽  
Tissue Samples ◽  
Group A ◽  
Group B

Azithromycin (AZM) therapeutic failure and relapses of patients treated with generic formulations have been observed in clinical practice. The main goal of this research was to compare in a preclinical study the serum exposure and lung tissue concentration of two commercial formulations AZM-based in murine model. The current study involved 264 healthy Balb-C. Mice were divided into two groups (n=44): animals of Group A (reference formulation -R-) were orally treated with AZM suspension at 10 mg/kg of b.w. Experimental animals of Group B (generic formulation -G-) received identical treatment than Group A with a generic formulation AZM-based. The study was repeated twice as Phase II and III. Serum and lung tissue samples were taken 24 h post treatment. Validated microbiological assay was used to determine the serum pharmacokinetic and lung distribution of AZM. After the pharmacokinetic analysis was observed, a similar serum exposure for both formulations of AZM assayed. In contrast, statistical differences (P<0.001) were obtained after comparing the concentrations of both formulations in lung tissue, being the values obtained for AUC and Cmax (AZM-R-) +1586 and 122%, respectively, than those obtained for AZM-G- in lung. These differences may indicate large differences on the distribution process of both formulations, which may explain the lack of efficacy/therapeutic failure observed on clinical practice.

scholarly journals Effect and mechanism of YH0618 granule on chemotherapy- induced hair loss in patients with breast cancer: study protocol for a randomized, double-blind, multi-center clinical trial

2019 ◽  
Author(s):  
Jie-shu You ◽  
Li Guo ◽  
Mei Huang ◽  
Xin-lei Shi ◽  
Man-di Lin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Clinical Trial ◽  
Chinese Medicine ◽  
Hair Loss ◽  
Double Blind ◽  
Kidney Deficiency ◽  
Group A ◽  
Group B

Abstract Background: Hair loss is one of the most common side effects of chemotherapy, which can cause persistent negative emotions, further affecting therapeutic effects and reducing the quality of life. However, there is no clinically safe and effective methods to solve the problem at present. Our previous clinical and animal studies showed that a medicinal and edible decoction YH0618 could significantly promote hair growth in cancer patients after chemotherapy, without interfering with the anti-tumor effect of chemotherapy. Besides, the theory of Chinese Medicine believes “Essence of the kidney is reflected on the hair”. Therefore, this study will further explore the efficacy of YH0618 granule on chemotherapy-induced hair loss in patients with breast cancer by a randomized, double-blind, multi-center clinical trial and elucidate the potential mechanism from the aspect of kidney deficiency or renal dysfunction. Methods/Design: Eligible breast cancer patients who will start chemotherapy will be randomly divided into group A (YH0618 granule) and group B (placebo). The chemotherapeutic agents contains Taxanes or/and Anthracyclines, and chemotherapy regimen will last at least 6 cycles with every three weeks a cycle. Subjects assigned to group A will receive YH0618 granules two times a day (6 g each time), 6 days a week, mixing with 300 ml warm water from the first to the fourth chemotherapy cycle. Subjects in group B will receive the placebo granule in the same manner. The primary outcome is the time point of occurrence of hair loss reaching grade II assessed by WHO Toxicity Grading Scale, and objective indexes of hair quality and hair follicle recorded by a hair and scalp detector before the fifth chemotherapy. Secondary outcomes include changes of facial color and thumbnails color, grading of thumbnails ridging, assessment of quality life, fatigue, routine blood test, hepatic and renal function, and some medical indicators which can reflect kidney deficiency in Chinese Medicine. Discussion: This research is of great significance for the treatment of cancer and improving the quality of life of patients. The study may provide the most direct evidence for meeting clinical needs and lay a solid scientific foundation for later product development. Trial registration: The trial was registered on 14 December 2018 at Chinese Clinical Trial Registry: ChiCTR1800020107.

scholarly journals Effect and mechanism of YH0618 granule on chemotherapy- induced hair loss in patients with breast cancer: study protocol for a randomized, double-blind, multi-center clinical trial

2019 ◽  
Author(s):  
Jie-shu You ◽  
Li Guo ◽  
Mei Huang ◽  
Xin-lei Shi ◽  
Man-di Lin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Clinical Trial ◽  
Chinese Medicine ◽  
Hair Loss ◽  
Double Blind ◽  
Kidney Deficiency ◽  
Group A ◽  
Group B

Abstract Background: Hair loss is one of the most common side effects of chemotherapy, which can cause persistent negative emotions, further affecting therapeutic effects and reducing the quality of life. However, there is no clinically safe and effective methods to solve the problem at present. Our previous clinical and animal studies showed that a medicinal and edible decoction YH0618 could significantly promote hair growth in cancer patients after chemotherapy, without interfering with the anti-tumor effect of chemotherapy. Besides, the theory of Chinese Medicine believes “Essence of the kidney is reflected on the hair”. Therefore, this study will further explore the efficacy of YH0618 granule on chemotherapy-induced hair loss in patients with breast cancer by a randomized, double-blind, multi-center clinical trial and elucidate the potential mechanism from the aspect of kidney deficiency or renal dysfunction. Methods/Design: Eligible breast cancer patients who will start chemotherapy will be randomly divided into group A (YH0618 granule) and group B (placebo). The chemotherapeutic agents contains Taxanes or/and Anthracyclines, and chemotherapy regimen will last at least 6 cycles with every three weeks a cycle. Subjects assigned to group A will receive YH0618 granules two times a day (6 g each time), 6 days a week, mixing with 300 ml warm water from the first to the fourth chemotherapy cycle. Subjects in group B will receive the placebo granule in the same manner. The primary outcome is the time point of occurrence of hair loss reaching grade II assessed by WHO Toxicity Grading Scale, and objective indexes of hair quality and hair follicle recorded by a hair and scalp detector before the fifth chemotherapy. Secondary outcomes include changes of facial color and thumbnails color, grading of thumbnails ridging, assessment of quality life, fatigue, routine blood test, hepatic and renal function, and some medical indicators which can reflect kidney deficiency in Chinese Medicine. Discussion: This research is of great significance for the treatment of cancer and improving the quality of life of patients. The study may provide the most direct evidence for meeting clinical needs and lay a solid scientific foundation for later product development. Trial registration: The trial was registered on 14 December 2018 at Chinese Clinical Trial Registry: ChiCTR1800020107.

scholarly journals The impact of At1r inhibition via losartan on the anti-leukaemic effects of doxorubicin in acute myeloid leukaemia

2019 ◽  
Vol 20 (2) ◽  
pp. 147032031985131
Author(s):  
Mehdi Ghasemi ◽  
Mufide Okay ◽  
Seyhan Turk ◽  
Ronak Naeemaee ◽  
Ebru Guver ◽  
...  
Keyword(s):  
Treatment Group ◽  
Drug Treatment ◽  
Cell Lines ◽  
The Other ◽  
Tumour Angiogenesis ◽  
Leukaemic Cells ◽  
Group A ◽  
Group B ◽  
Drug Treatment Group ◽  
Acute Myeloid

Introduction: Bone marrow renin–angiotensin system(RAS) modulates acute myeloid leukaemia(AML).The aim of this study is to clarify the relationships between RAS and AML, and to show the effect of losartan and doxorubicin treatment in AML cell lines. Methods: AML cell lines including CESS, HL-60, MO-1, P31/FUJ, GDM-1 and KASUMI-3 were used as models in this study. Results: After treating the six AML cell lines with a combination of losartan and doxorubicin, they were divided into two groups based on their behaviour: one became more sensitive to drug treatment (Group A) and the other had no change observed in behaviour after drug treatment (Group B). In silico analyses showed that Group A is involved in cellular apoptosis, while Group B is involved in tumour angiogenesis further supporting the in vitro results. Conclusion: The combined treatment of the AML cell lines with losartan and doxorubicin resulted in an increase in sensitivity of some of the cell lines. Those leukaemic cells are modulated via the induction of apoptosis, whereas the other cells resistant to the drug treatment are closely related to tumour angiogenesis indicating that RAS-AT1R seems to be differently expressed in different leukaemic blast cells and tumour microenvironments. Pharmaco-biological actions of RAS inhibitors may be different in distinct leukaemic cells based on the pathological behaviour of AML genomic subtypes.

scholarly journals PO-263 Clinical rehabilitation of external humeral epicondylitisby ginger moxibustion and its combination therapy

2018 ◽  
Vol 1 (5) ◽  
Author(s):  
Xiao Zhang ◽  
Pengyi Zhang
Keyword(s):  
Chinese Medicine ◽  
Treatment Group ◽  
Total Effective Rate ◽  
Daily Life ◽  
Tennis Elbow ◽  
Effective Rate ◽  
Control Group ◽  
Treatment Groups ◽  
Group A ◽  
Group B

Objective External humeral epicondylitis, also known as “tennis elbow”, is a chronic motor inflammation caused by non-normative movement or excessive pressure and torsion of the forearm tendon and bone. The external humeral epicondylitis occursmostly in tennis, badminton, table tennis, fencing, throwing, gymnastics and other sport programs. Because it has the highest incidence in tennis, everyone is used to call it "tennis elbow". Those who have repeatedly used force to do elbow activities in daily life, such as housewives, bricklayers, woodworkers, etc., are also susceptible to this disease. Therefore, the disease affects a large number of occupations and sports. The conventional medical nsurgery leads to a large wound area and a long recovery time, which is easy to shorten the sportlife of the patient. The conservative Chinese medicine ginger moxibustion therapy could clear the meridians and organs by stimulating the acupoint of the human body. This moxibustion therapy has the advantages of small trauma, low cost, comprehensive treatment and small side effects by adjusting the blood, and would not bring inconvenience to patients' daily life and normal exercises. This paper aims to use a conservative treatment-Traditional Chinese medicine ginger moxibustion and its composite therapy to rehabilitate the external humeral epicondylitis systematically and compare the rehabilitation effects of different compound therapy to provide a basis for tennis elbow’s rehabilitation. Methods Eighty-four tennis elbow patients were divided into three treatment groups and one control group randomly, subject and observer-double-blind, third-party evaluation. The treatment groups included a group of ginger moxibustion named A,a group of floating needle combined with ginger moxibustion named B, and a group of Yunnan BaiYao aerosol combined with ginger moxibustion named C, the control group named D, 21 people/group. In the treatment group A, acupuncture points were taken from A’shi, Quchi and Hand Sanli, ginger moxibustion treatment,5 moxibustion columns/time, once every other day, 5 times as a course of treatment, observethe effect after two courses; The group B was first treated with floating needles at three acupoints, and after 2 minutes treated as group A, 5 moxibustion columns each time, once every other day, 5 times as a course of treatment, observe the effect after two courses as well;The group C was first sprayed on Yunnan Baiyaoaeroso in three acupoints,two minutes later, treated as group A, use 5 moxibustion columns each time, once every other day, 5 times as a course of treatment, observe the effect after two courses. The control group was treated with ginger laser treatment at the same acupoints, keep as the same treatment as group A, observethe effect after two courses. The shoulder-arm-hand disability score (DASH) was use for the main observation index, and pain (VAS), painless grip strength (PFGS) and pressure pain threshold (PPT) were meanwhile used as secondary observation indicators. Results  Four sets of experimental data were submitted to Shandong University of Traditional Chinese Medicine. The analysis of results showed that patients in treatment groups improved their function and relieved the pain significantly much better than the ginger-fake laser control group within 3-12 months of treatment completion. In the treatment group, the total effective rate of the group A-- treated with ginger-free moxibustion was 80%, and the total effective rate of the group C --treated with Yunnan Bai Yao aerosol combined with ginger moxibustion was 85%,and the total effective rate of the group B--treatment with floating needle combined with ginger moxibustion was 92%, but the total effective rate of the control group was 10%. Conclusions The clinical recovery evaluation and index assessment results showed that ginger moxibustion and its combination therapy had significant curative effects on patients suffering external humeral epicondylitis. The addition of auxiliary means also promoted the rehabilitation effects, further proving the Traditional Chinese medical effects. The method could significantly improve the rehabilitation of external humeral epicondylitis. The research made a bold exploration for the multi-organizational cooperation mode of TCM compound therapy in the field of sport injury habilitation, and opened a new way for its application ofclinical research.  

scholarly journals Effect of Perineum Block Anesthesia Combined with Unprotected Perineal Delivery on the Perineal Integrity Rate and Maternal-Infant Outcomes in Primiparas Taking Health Products Containing Traditional Chinese Medicine

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Xu Liu ◽  
Jianyun Ge ◽  
Jiejie Zhang ◽  
Boxiang Du
Keyword(s):  
Quality Of Life ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Infant Outcomes ◽  
Labor Duration ◽  
Health Products ◽  
Group A ◽  
General Data ◽  
Group B

Objective. The purpose of the study was to investigate the effect of perineum block anaesthesia combined with unprotected perineal delivery on the perineal integrity rate and maternal-infant outcomes in primiparas taking health products containing traditional Chinese medicine (TCM). Methods. A total of 120 puerperae admitted to our hospital from July 2019 to July 2020 were selected as study subjects and divided into group A (n = 60) and group B (n = 60), according to the number table method. Both groups took health products containing TCM, and the puerperae in group A received perineum block anaesthesia combined with unprotected perineal delivery, while those in group B were treated with routine delivery combined with routine protected perineal delivery. After that, the effect of different delivery modes on the perineal integrity rate and maternal-infant outcomes in puerperae was analyzed by the comparison of delivery condition, perineal condition, and postpartum quality of life between the two groups. Results. There were no significant differences in average age and other general data between the two groups ( P > 0.05 ); the duration in first, second, and third stages of labor in group A was significantly lower than that in group B ( P < 0.001 ); the Apgar score in group A was significantly higher than that in group B ( P < 0.001 ); the number of puerperae with integrated perineum in group A was significantly higher than that in group B ( P < 0.05 ), while the number of puerperae receiving episiotomy in group A was significantly lower than that in group B ( P < 0.05 ); the quality of life score in group A was significantly higher than that in group B ( P < 0.001 ); the incidence of maternal postpartum complications in group A was significantly lower than that in group B ( P < 0.05 ). Conclusion. Perineum block anaesthesia combined with unprotected perineal delivery can effectively shorten maternal labor duration, improve perineal integrity rate, and reduce laceration of perineum, with a significant therapeutic effect, which is worthy of application and promotion.

Sign in / Sign up

Export Citation Format

Share Document